Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Centre d'Infection et d'Immunité de Lille, Lille, France, University Lille, F-59000, Lille, France.
CHU Lille, Institut Pasteur de Lille, Inserm, CNRS, UMR2014-US41-PLBS-6 Plateformes Lilloises de Biologie & Santé, University Lille, F-59000, Lille, France.
Crit Care. 2020 Oct 15;24(1):611. doi: 10.1186/s13054-020-03320-8.
Gut dysbiosis due to the adverse effects of antibiotics affects outcomes of lung infection. Previous murine models relied on significant depletion of both gut and lung microbiota, rendering the analysis of immune gut-lung cross-talk difficult. Here, we study the effects of antibiotic-induced gut dysbiosis without lung dysbiosis on lung immunity and the consequences on acute P. aeruginosa lung infection.
C57BL6 mice received 7 days oral vancomycin-colistin, followed by normal regimen or fecal microbial transplant or Fms-related tyrosine kinase 3 ligand (Flt3-Ligand) over 2 days, and then intra-nasal P. aeruginosa strain PAO1. Gut and lung microbiota were studied by next-generation sequencing, and lung infection outcomes were studied at 24 h. Effects of vancomycin-colistin on underlying immunity and bone marrow progenitors were studied in uninfected mice by flow cytometry in the lung, spleen, and bone marrow.
Vancomycin-colistin administration induces widespread cellular immunosuppression in both the lung and spleen, decreases circulating hematopoietic cytokine Flt3-Ligand, and depresses dendritic cell bone marrow progenitors leading to worsening of P. aeruginosa lung infection outcomes (bacterial loads, lung injury, and survival). Reversal of these effects by fecal microbial transplant shows that these alterations are related to gut dysbiosis. Recombinant Flt3-Ligand reverses the effects of antibiotics on subsequent lung infection.
These results show that gut dysbiosis strongly impairs monocyte/dendritic progenitors and lung immunity, worsening outcomes of P. aeruginosa lung infection. Treatment with a fecal microbial transplant or immune stimulation by Flt3-Ligand both restore lung cellular responses to and outcomes of P. aeruginosa following antibiotic-induced gut dysbiosis.
抗生素的不良反应导致肠道菌群失调会影响肺部感染的结果。以前的鼠模型依赖于对肠道和肺部微生物群的大量消耗,这使得对免疫肠道-肺部交叉对话的分析变得困难。在这里,我们研究了抗生素诱导的肠道菌群失调而不引起肺部菌群失调对肺部免疫的影响,以及对急性铜绿假单胞菌肺部感染的后果。
C57BL6 小鼠接受 7 天口服万古霉素-黏菌素,然后接受正常方案或粪便微生物移植或 Fms 相关酪氨酸激酶 3 配体(Flt3-Ligand)2 天,然后经鼻内接种铜绿假单胞菌菌株 PAO1。通过下一代测序研究肠道和肺部微生物群,在 24 小时研究肺部感染结果。通过流式细胞术在未感染的小鼠的肺部、脾脏和骨髓中研究万古霉素-黏菌素对基础免疫和骨髓祖细胞的影响。
万古霉素-黏菌素给药在肺部和脾脏中诱导广泛的细胞免疫抑制,降低循环造血细胞因子 Flt3-Ligand,并抑制树突状细胞骨髓祖细胞,导致铜绿假单胞菌肺部感染结果恶化(细菌负荷、肺损伤和存活率)。粪便微生物移植的逆转这些效应表明这些改变与肠道菌群失调有关。重组 Flt3-Ligand 逆转了抗生素对随后肺部感染的影响。
这些结果表明,肠道菌群失调强烈损害单核细胞/树突状祖细胞和肺部免疫,使铜绿假单胞菌肺部感染的结果恶化。粪便微生物移植或 Flt3-Ligand 的免疫刺激治疗都恢复了抗生素诱导的肠道菌群失调后对铜绿假单胞菌的肺部细胞反应和结果。